Skip to main content

The life sciences industry is arguably the most dynamic sector of the U.S. economy, with the pace of change and innovation in the industry felt globally. Bilzin Sumberg has its fingers on the pulse of this diverse and critical field. The firm's attorneys have represented pharmaceutical, medical device and diagnostics companies, and biotech companies, among others, helping them to navigate the complex business and legal issues they face as they bring life-changing products to market.

The firm's counsel has been sought for conducting securities offerings (both public and private), and mergers, acquisitions and dispositions of life sciences companies and product lines, as well as for negotiating and documenting commercialization transactions on behalf of those companies. Such transactions include supply, manufacturing, licensing, and distribution agreements with inventors of technology and intellectual property, external suppliers and original equipment manufacturers, and global distribution networks; joint venture and strategic alliance agreements between the firm's clients and other industry participants; and clinical trials, educational grant, consulting, and fellowship agreements between firm clients and research institutions, and health care providers.

Bilzin Sumberg also advises its life sciences clients on corporate governance matters, financing and day-to-day operations, periodic securities reporting and compliance, and their real estate needs. The firm's life sciences clients come of all stages of the corporate life cycle, from start-up and development-stage to growth and consolidation to exit strategies.

EXPERIENCE
EXPERIENCE
Representation of client in the acquisition of a privately-held veterinary pharmaceutical manufacturing company by a publicly-traded pharmaceutical company for $440 million of consideration consisting of stock and cash and redemption of indebtedness.
EXPERIENCE
Representation of client as issuer’s counsel in a Rule 144A offering of $144 million senior convertible debt for a clinical drug development services company.
EXPERIENCE
Represented owner of intellectual property and raw materials in a manufacturing and supply agreement for an over-the-counter, transdermal pharmaceutical product.
EXPERIENCE
Representation of client in the acquisition of a publicly-traded developer and manufacturer of drug delivery technology by a publicly-traded pharmaceutical company for consideration consisting of stock.
EXPERIENCE
Representation of client as issuer’s counsel in a $133 million follow-on equity offering for a clinical drug development services company.
EXPERIENCE
Represented distributor in a supply and distribution agreement for automated diagnostics systems and related consumables and accessories.
INSIGHTS
RELATED PEOPLE
David M. Seifer

David M. Seifer

Partner
Alan D. Axelrod

Alan D. Axelrod

Partner
Adrian K. Felix

Adrian K. Felix

Partner
Jay M. Sakalo

Jay M. Sakalo

Partner, Business Finance & Restructuring and Corporate Practice Group Leader
Jeffrey I. Snyder

Jeffrey I. Snyder

Partner, Assistant General Counsel